

## EQA round: IFT1/26 - Immunophenotypisation

Deadline: 27.4.2026

Setup: groups - R (manufacturer of kit)

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessed

CVP = consensus of all participants

N<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(259) HLA-B27</b>		61			61	60	98
<b>Sample A</b>		61			61	60	98
(12) Beckman Coulter	>	2	3,3	Inconclusive result (borderline)			
	CVP >>>	44	72	Positive			
(36) Immunotech	CVP >>>	2	3,3	Positive			
(88) Becton Dickinson		1	1,6	Negative			
	>	2	3,3	Inconclusive result (borderline)			
	CVP >>>	7	11	Positive			
(177) Mindray	CVP >>>	3	4,9	Positive			
<b>Sample B</b>		61			61	61	100
(12) Beckman Coulter	CVP >>>	46	75	Negative			
(36) Immunotech	CVP >>>	2	3,3	Negative			
(88) Becton Dickinson	CVP >>>	10	16	Negative			
(177) Mindray	CVP >>>	3	4,9	Negative			